Santaris Presents Data on Tiny LNAs for miRNA Family Inhibition

In some cases, knocking down an entire family of microRNAs will be required to see a therapeutic benefit, according to Santaris CSO Henrik Orum. To address this issue, the company has been developing 8 nucleotide-long LNAs that are perfectly complementary to an miRNA seed region.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.